Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential gene expression of retrotransposons (LTR and non-LTR) in peripheral blood leukocytes of people with gout.

Arthritis research & therapy·2026
Same author

Pan-Cancer Bioinformatics-Guided Evaluation of San-Huang-Xie-Xin-Tang Identifies Kidney Renal Clear Cell Carcinoma as a Potentially Responsive Cancer Type.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

High Serum IgE is Associated with Risk of Severe Exacerbations Among Non-Eosinophilic Bronchiectasis.

Lung·2026
Same author

Reply to Letter to the Editor regarding "Impact of sex on the development of bacteremia in critically ill burn patients: A retrospective cohort study".

Burns : journal of the International Society for Burn Injuries·2026
Same author

Electron-Deficient Bimetallic Oxide Electrocatalyst for High-Efficiency Ammonia Synthesis Under Ambient Conditions.

ChemSusChem·2026
Same author

Corrigendum to "Impact of sex on the development of bacteremia in critically ill burn patients: A retrospective cohort study" [Burns 52 (2) (2026) 107845].

Burns : journal of the International Society for Burn Injuries·2026

Related Experiment Video

Updated: Apr 30, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K

Developing and Evaluating the HRM Technique for Identifying Cytochrome P450 2D6 Polymorphisms.

Hsiu-Chin Lu1,2, Ya-Sian Chang1,3, Chun-Chi Chang4

  • 1Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.

Journal of Clinical Laboratory Analysis
|May 7, 2014
PubMed
Summary

High-resolution melting analysis efficiently identifies Cytochrome P450 2D6 (CYP2D6) genetic variations. This faster, cost-effective method accurately genotypes common CYP2D6 polymorphisms in Chinese populations.

Keywords:
CYP2D6direct sequencinghigh-resolution melting analysis

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria
10:27

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria

Published on: November 10, 2015

12.2K

Related Experiment Videos

Last Updated: Apr 30, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria
10:27

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria

Published on: November 10, 2015

12.2K

Area of Science:

  • Pharmacogenomics
  • Molecular Diagnostics

Background:

  • Cytochrome P450 2D6 (CYP2D6) is crucial for metabolizing numerous drugs.
  • Genetic variations in CYP2D6 significantly impact drug efficacy and safety.
  • Accurate identification of CYP2D6 polymorphisms is clinically essential for personalized medicine.

Purpose of the Study:

  • To develop and validate a high-resolution melting (HRM) analysis for identifying CYP2D6 genetic polymorphisms.
  • To assess the efficiency and accuracy of HRM compared to traditional sequencing methods.

Main Methods:

  • Genomic DNA extraction from 71 healthy individuals.
  • Sequencing of all nine CYP2D6 exons.
  • Screening of CYP2D6 polymorphisms using HRM analysis.
  • Detection of multiple CYP2D6 genotypes (*1, *2, *4, *10, *14, *21, *39, *41).

Main Results:

  • HRM analysis successfully genotyped all samples with 100% sensitivity, specificity, and predictive values.
  • The method accurately identified common CYP2D6 alleles (*1, *2, *10, *41) and specific single nucleotide polymorphisms (SNPs).
  • HRM results were concordant with direct sequencing, demonstrating its reliability.

Conclusions:

  • High-resolution melting analysis offers a rapid, cost-effective, and accurate alternative to direct sequencing for CYP2D6 genotyping.
  • This validated HRM method is an efficient tool for clinical application in determining CYP2D6 polymorphisms.